Cite
HARVARD Citation
Deville, J. et al. (n.d.). 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort. Journal for immunotherapy of cancer. p. A163. [Online].